New hope for hard-to-treat blood cancer: BR101 injection enters human testing
NCT ID NCT07537049
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called BR101 in 10 people with multiple myeloma that has returned or not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at whether the drug helps shrink the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- MRI scans may reveal hidden clues to myeloma relapse risk
- Can a dual immunotherapy erase hidden myeloma cells?
- Does CAR-T therapy affect the brain? a study investigates
- Can a single gene therapy turn the body into a Cancer-Fighting factory?
- Can a closer look at bone complications in multiple myeloma improve rehabilitation?
- Gene-Guided Chemo-Free strategy targets AL amyloidosis